Literature DB >> 16614630

Management strategies of dyslipidemia in the elderly: 2005.

Tarek Helmy1, Amar D Patel, Fadi Alameddine, Nanette K Wenger.   

Abstract

During the past 3 years, the treatment of dyslipidemia has evolved significantly. The impact of recent trial data on management strategies in older patients is especially important, because the elderly segment of the US population continues to grow. Several clinical trials have been completed since the publication of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III guidelines were published in 2001. Recent trial data strongly support the use of lipid-lowering therapy in the elderly population. Although therapeutic lifestyle changes remain highly important, supplementation with lipid-lowering therapy has been shown to reduce the risk of cardiovascular events in both primary and secondary prevention models. Compelling data noted from recent clinical trials have prompted the NCEP to publish an updated report that addresses the significant interim developments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16614630      PMCID: PMC1681733     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  35 in total

1.  Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association.

Authors:  G F Fletcher; G Balady; S N Blair; J Blumenthal; C Caspersen; B Chaitman; S Epstein; E S Sivarajan Froelicher; V F Froelicher; I L Pina; M L Pollock
Journal:  Circulation       Date:  1996-08-15       Impact factor: 29.690

2.  Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons.

Authors:  M C Corti; J M Guralnik; M E Salive; T Harris; L Ferrucci; R J Glynn; R J Havlik
Journal:  Ann Intern Med       Date:  1997-05-15       Impact factor: 25.391

3.  Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

Authors:  T A Miettinen; K Pyörälä; A G Olsson; T A Musliner; T J Cook; O Faergeman; K Berg; T Pedersen; J Kjekshus
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

4.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

5.  In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461.

Authors:  M Van Heek; C F France; D S Compton; R L McLeod; N P Yumibe; K B Alton; E J Sybertz; H R Davis
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

6.  Hypertriglyceridemia as a cardiovascular risk factor.

Authors:  M A Austin; J E Hokanson; K L Edwards
Journal:  Am J Cardiol       Date:  1998-02-26       Impact factor: 2.778

7.  Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.

Authors:  M de Lorgeril; P Salen; J L Martin; I Monjaud; J Delaye; N Mamelle
Journal:  Circulation       Date:  1999-02-16       Impact factor: 29.690

8.  The emergence of triglycerides as a significant independent risk factor in coronary artery disease.

Authors:  G Assmann; H Schulte; H Funke; A von Eckardstein
Journal:  Eur Heart J       Date:  1998-10       Impact factor: 29.983

9.  Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.

Authors:  Theodore Feldman; Michael Koren; William Insull; James McKenney; Helmut Schrott; Andrew Lewin; Sukrut Shah; Michelle Sidisin; Meehyung Cho; Debra Kush; Yale Mitchel
Journal:  Am J Cardiol       Date:  2004-06-15       Impact factor: 2.778

10.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.